Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03275064 · ClinicalTrials.gov registry record · Phase 2
Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT03275064 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 142 participants.
The verdict
NCT03275064, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
The purpose of this two-part study is to assess the efficacy, safety and tolerability of multiple intra-articular (i.a.) injections of LNA043, in regenerating the articular surface in patients with cartilage lesions of the knee (Part A) and knee osteoarthritis (Part B).
Interventions
- OTHER Placebo
- BIOLOGICAL LNA043
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2017-09-12 |
| Est. Completion | 2022-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03275064
The ClinicalTrials.gov registry entry for NCT03275064 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03275064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03275064 about?
NCT03275064 is a clinical study titled "Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.". The purpose of this two-part study is to assess the efficacy, safety and tolerability of multiple intra-articular (i.a.) injections of LNA043, in regenerating the articular surface in patients with cartilage lesions of the knee (Part A) and knee osteoarthritis (Part B).
What is the current status of trial NCT03275064?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2017-09-12. Estimated completion is 2022-09-06.
What interventions are being tested in trial NCT03275064?
The interventions under investigation include: Placebo (OTHER), LNA043 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03275064?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.